文献速递浆细胞疾病

表达骨保护素变体的间充质干细胞在多发性骨髓瘤小鼠模型中抑制骨溶解

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.
PubMed 文献 · Blood Adv · 2017-11-21

本研究在小鼠多发性骨髓瘤骨播散模型中测试了一种细胞疗法:将基因工程改造表达骨保护素(OPG)变体的间充质干细胞(MSC)用于治疗,该变体保留结合RANKL的能力但不结合TRAIL。骨骼重塑结果显示,该再生干细胞疗法对骨髓瘤主要骨骼播散区域的骨髓瘤诱导的骨溶解性骨损伤具有显著保护作用,提示该疗法有望用于治疗骨髓瘤患者的骨溶解性损伤。

要点

  • 表达保留RANKL结合力但不结合TRAIL的OPG变体的MSC,在多发性骨髓瘤小鼠模型中显著保护骨髓瘤诱导的骨溶解性骨损伤。
  • 多发性骨髓瘤患者中RANKL表达增加增强破骨细胞活性,OPG及MSC成骨潜能显著降低。
  • OPG直接用于治疗受限,因其结合TRAIL使肿瘤细胞抵抗TRAIL诱导的凋亡。

核心结论

  • 表达保留RANKL结合力但不结合TRAIL的OPG变体的MSC细胞疗法,在小鼠多发性骨髓瘤骨播散模型中显著保护骨髓瘤诱导的骨溶解性骨损伤。

研究设计与样本

  • 研究建立了小鼠骨播散性多发性骨髓瘤疾病模型,并测试了经基因工程改造表达OPG变体的MSC细胞疗法。

主要发现

  • 骨骼重塑结果显示,该再生干细胞疗法对骨髓瘤主要骨骼播散区域的骨髓瘤诱导的骨溶解性骨损伤具有显著保护作用。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current treatment options for multiple myeloma (MM) osteolytic lesions are mainly combinations of chemotherapy and other small-molecule inhibitors, but toxic side effects still remain a major concern. Studies have shown that osteoclast activity is enhanced in MM patients through increased expression of receptor activator of nuclear factor κB ligand (RANKL), triggering RANK signaling on osteoclast precursors, which results in aggressive bone resorption. Furthermore, osteoprotegerin (OPG), a decoy receptor for RANKL, and the osteogenic potential of mesenchymal stem cells (MSCs) are significantly decreased in myeloma patients with multiple bone lesions. Thus, the use of OPG as a therapeutic molecule would greatly decrease osteolytic damage and reduce morbidity. However, in addition to inhibiting osteoclast activation, OPG binds to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), thereby rendering the tumor cells resistant to TRAIL-induced apoptosis and limiting the use of OPG for therapy. The present study developed a bone-disseminated myeloma disease model in mouse and successfully tested a cell therapy approach using MSCs, genetically engineered to express OPG variants that retain the capacity to bind RANKL, but do not bind TRAIL. Our results of skeletal remodeling following this regenerative stem cell therapy with OPG variants indicated a significant protection against myeloma-induced osteolytic bone damage in areas of major myeloma skeletal dissemination, suggesting the potential of this therapy for treating osteolytic damage in myeloma patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Higgs JT, Lee JH, Wang H, et al. Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma. Blood Adv. 2017. PMID: 29296887. doi:10.1182/bloodadvances.2017007310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。